J-104,871, a novel farnesyltransferase inhibitor, blocks ras farnesylation in vivo in a farnesyl pyrophosphate-competitive manner

Molecular Pharmacology

Volumn 54, Issue 1, 1998, Pages 1-7

  Yonemoto, Mari ^a,b   Satoh, Toshihiko ^a   Arakawa, Hiroharu ^a   Suzuki Takahashi, Ikuko ^a   Monden, Yoshiaki ^a   Kodera, Tsutomu ^a   Tanaka, Kenji ^a   Aoyama, Tetsuya ^a   Iwasawa, Yoshikazu ^a   Kamei, Toshio ^a   Nishimura, Susumu ^a   Tomimoto, Koji ^a  

^a Banyu Pharmaceutical Co   (Japan)

^b BANYU PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 [N [5 (2 BENZOXAZOLYL) 1 METHYL 2 [3,4 (METHYLENEDIOXY)PHENYL] 4 PENTENYL] N (2 NAPHTHYLMETHYL)CARBAMOYL] 1,3 DIOXOLANE 2,2,4 TRICARBOXYLIC ACID; MEVINOLIN; PROTEIN FARNESYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PYROPHOSPHATE; RAS PROTEIN; SQUALENE SYNTHASE; SQUALENE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG; ZARAGOZIC ACID A;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNOBLOTTING; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; ONCOGENE RAS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; RAT; TUMOR GROWTH;

EID: 0031820282     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.54.1.1     Document Type: Article

References (37)

1. Aoyama T, Satho T, Yonemoto M, Shibata J, Nonoshita K, Arai DS, Kawakami K, Iwasawa Y, Sano H, Tanaka K, Monden Y, Kodera T, Arakawa H, Takahashi I, Kamei T, and Tomimoto K (1998) A new class of highly potent farnesyl diphosphate-competitive inhibitors of farnesyltransferase. J Med Chem 41:143-147.
2. Barbacid M (1987) ras Genes. Annu Rev Biochem 56:779-827.
3. Barbacid M (1990) ras Oncogenes: their role in neoplasia. Eur J Clin Invest 20:225-235.
4. Bergstrom, JD, Kurtz MM, Rew DJ, Amend AM, Karkas JD, Bostedor RG, Bansal VS, Dufresne C, VanMiddlesworth F, Hensens OD, Liesch JM, Zink DL, Wilson KE, Onishi J, Milligan JA, Bills G, Kaplan L, Omstead MN, Jenkins RG, Huang L, Meinz MS, Quinn L, Burg RW, Kong YL, Mochales S, Mojena M, Martin I, Pelaez F, Diez MT, and Alberts AW (1993) Zaragozic acids: a family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase. Proc Natl Acad Sci USA 90:80-84.
5. Bishop WR, Bond R, Petrin J, Wang L, Patton R, Doll R, Njoroge G, Catino J, Schwartz J, Windsor W, Syto R, Schwartz J, Carr D, James L, and Kirschmeier P (1995) Novel tricylic inhibitors of farnesyl protein transferase. J Biol Chem 270:30611-30618.
6. Bos JL (1989) ras Oncogenes in human cancer: a review. Cancer Res 49:4682-4689.
7. Bourne HR, Sanders DA, and McCormick F (1991) The GTPase superfamily: conserved structure and molecular mechanism. Nature (Lond) 349:117-127.
8. Fang LZ, John FM, and Patrick JC (1994) Properties and kinetic mechanism of recombinant mammalian protein geranylgeranyltransferase type I. J Biol Chem 269:23465-23470.
9. Garcia AM, Rowell C, Ackermann K, Kowalczyk JJ, and Lewis MD (1993) Peptidomimetic inhibitors of ras farnesylation and function in whole cells. J Biol Chem 268:18415-18418.
10. Gibbs JB (1991) Ras C-terminal processing enzymes-new drug targets? Cell 65:1-4.
11. Gibbs JB, Pompliano DL, Mosser SD, Rands E, Lingham RB, Singh SB, Scolnick EM, Kohl NE, and Oliff A (1993) Selective inhibition of farnesyl-protein transferase blocks ras processing in vivo. J Biol Chem 268:7617-7620.
12. Gibbs JB, Sigal IS, Poe M, and Scolnick EM (1984) Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules. Proc Natl Acad Sci USA 81:5704-5708.
13. Hancock JF, Magee AI, Childs JE, and Marshall CJ (1989) All ras proteins are polyisoprenylated but only some are palmitoylated. Cell 57:1167-1177.
14. Horie M, Tsuchiya Y, Hayashi M, Iida Y, Iwasawa Y, Nagata Y, Sawasaki Y, Fukuzumi H, Kitani K, and Kamei T (1990) NB-598: a potent competitive inhibitor of squalene epoxidase. J Biol Chem 265:18075-18078.
15. Iwasawa Y, Hayashi M, Nomoto T, Shibata J, Mitsuya M, Hirota K, Yonemoto M, Kamei T, Miura K, and Tomimoto K (1995) Synthesis and biological activity of J-104,118, a novel, potent inhibitor of squalene synthase. Bioorg Med Chem Lett 5:1989-1994.
16. Iwasawa Y, Shibata J, Mitsuya M, Masaki H, Hayashi M, Kanno T, Sawasaki Y, Hisaka A, Kamei T, Miura K, and Tomimoto K (1996) J-104,123, a novel and orally active inhibitor of squalene synthase: stereoselective synthesis and cholesterol lowering effects in dogs. Bioorg Med Chem Lett 6:463-466.
17. James GL, Goldstein JL, and Brown MS (1995) Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J Biol Chem 270:6221-6226.
18. James G, Goldstein JL, and Brown MS (1996) Resistance of K-RasBV12 proteins to farnesyltransferase inhibitors in Rat1 cells. Proc Natl Acad Sci USA 93:4454-4458.
19. James GL, Goldstein JL, Brown MS, Rawson TE, Somers TC, McDowell RS, Crowley CW, Lucas BK, Levinson AD, and Marsters JC Jr (1993) Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. Science (Washington DC) 260:1937-1942.
20. Kato K, Cox AD, Hisaka MM, Graham SM, Buss JE, and Der CJ (1992) Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci USA 89:6403-6407.
21. Kohl NE, Wilson FR, Mosser SD, Giuliani E, DeSolms SJ, Conner MW, Anthony NJ, Holtz WJ, Gomez RP, Lee T-J, Smith RL, Graham SL, Hartman GD, Gibbs JB, and Oliff A (1994) Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc Natl Acad Sci USA 91:9141-9145.
22. Lowy DR (1993) Function and regulation of ras. Annu Rev Biochem 62:851-891.
23. McNamara DJ, Dobrusin E, Leanarrd DM, Shuler KR, Kaltenbronn JS, Quin J III, Bur S, Thomas CE, Doherty AM, Scholten JD, Zimmerman KK, Gibbs BS, Gowan RC, Latash MP, Leopold WR, Przybranowski SA, and Sebolt-Leopold JS (1997) C-terminal modifications of histidyl-N-benzylglycinamides to give improved inhibition of Ras farnesyltransferase, cellular activity and anticancer activity in mice. J Med Chem 40:3319-3322.
24. Nagasu T, Yoshimatsu K, Rowell C, Lewis MD, and Garcia AM (1995) Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res 55:5310-5314.
25. Pompliano DL, Rands E, Schaber MD, Mosser SD, Anthony NJ, and Gibbs JB (1992) Steady-state kinetic mechanism of Ras farnesyl:protein transferase. Biochemistry 31:3800-3807.
26. ReissY, Goldstein JL, Seabra MC, Casey PJ, and Brown MS (1990) Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides. Cell 62:81-88.
27. Reiss Y, Seabra MC, Armstrong SA, Slaughter CA, Goldstein JL, and Brown MS (1991) Nonidentical subunits of p21H-ras farnesyltransferase. J Biol Chem 266:10672-10677.
28. Rodenhuis S (1992) ras and human tumors. Semin Cancer Biol 3:241-247.
29. Rowell CA, Kowalczyk JJ, Lewis MD, and Garcia AM (1997) Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo. J Biol Chem 272:14093-14097.
30. Schafer WR, Kim R, Sterne R, Thorner J, Kim S-H, and Rine J (1989) Genetic and pharmacological suppression of oncogenic mutations in ras genes of yeast and humans. Science (Washington DC) 245:379-385.
31. Scheffzek K, Ahmadian MR, Kabsch W, Wiesmüler L, Lautwein A, Schmitz F, and Wittinghofer A (1997) The ras-rasGAP complex: structural basis for GTPase activation and its loss in oncogenic ras mutants. Science (Washington DC) 277:333-338.
32. Sepp-Lorenzino L, Ma Z, Rands E, Kohl NE, Gibbs JB, Oliff A, and Rosen NA (1995) Peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and independent growth of human tumor cell lines. Cancer Res 55:5302-5309.
33. Shin S, Freeman VH, Risser R, and Pollack R (1975) Tumorigenicity of virus-transformed cells in nude mice is correlated specifically with anchorage independent growth in vitro. Proc Natl Acad Sci USA 72:4435-4439.
34. Sun J, Qian Y, Hamilton AD, and Sebti SM (1995) Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion. Cancer Res 55:4243-4247.
35. Willumsen BM, Christensen A, Hubbert NL, Papageorge AG, and Lowy DR (1984) The p21 ras C-terminus is required for transformation and membrane association. Nature (Lond) 310:583-586.
36. Zhang FL and Casey PJ (1996) Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 65:241-269.
37. Zhang FL, Kirschmeier P, Carr D, James L, Bond RW, Wang L, Patton R, Windsor WT, Syto R, Zhang R, and Bishop WR (1997) Characterization of Ha-Ras, N-Ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I. J Biol Chem 272:10232-10239.